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ABSTRACT
Background and aims Prior research has found bidirectional associations between psychotic experiences (PEs) and se-
lected substance use disorders. We aimed to extend this research by examining the bidirectional association between PEs
and various types of substance use (SU) and substance use disorders (SUDs), and the inﬂuence of antecedent mental dis-
orders on these associations. Design, setting, participants and measurements We used data from the World Health
Organization World Mental Health surveys. A total of 30902 adult respondents across 18 countries were assessed for
(a) six types of life-time PEs, (b) a range of types of SU and DSM-IV SUDs and (c) mental disorders using the Composite In-
ternational Diagnostic Interview. Discrete-time survival analyses based on retrospective age-at-onset reports examined the
bidirectional associations between PEs and SU/SUDs controlling for antecedent mental disorders. Findings After
adjusting for demographics, comorbid SU/SUDs and antecedent mental disorders, those with prior alcohol use disorders
[odds ratio (OR) = 1.6, 95% conﬁdence interval (CI) = 1.2–2.0], extra-medical prescription drug use (OR = 1.5, 95%
CI = 1.1–1.9), alcohol use (OR = 1.4, 95% CI = 1.1–1.7) and tobacco use (OR = 1.3, 95% CI = 1.0–1.8) had increased
odds of subsequent ﬁrst onset of PEs. In contrast, those with temporally prior PEs had increased odds of subsequent onset of
tobacco use (OR = 1.5, 95% CI = 1.2–1.9), alcohol use (OR = 1.3, 95% CI = 1.1–1.6) or cannabis use (OR = 1.3, 95%
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CI = 1.0–1.5) as well as of all substance use disorders (ORs ranged between 1.4 and 1.5). There was a dose response re-
lationship between both count and frequency of PEs and increased subsequent odds of selected SU/SUDs.
Conclusions Associations between psychotic experiences (PEs) and substance use/substance use disorders (SU/SUDs)
are often bidirectional, but not all types of SU/SUDs are associated with PEs. These ﬁndings suggest that it is important
to be aware of the presence of PEs within those with SUDs or at risk of SUDs, given the plausibility that they may each im-
pact upon the other.
Keywords Alcohol, cannabis, mental disorder, nicotine, prescription drug, psychotic experiences, substance abuse
disorder, substance dependence disorder, substance use, tobacco.
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INTRODUCTION
Although it is widely acknowledged that acute intoxica-
tion with various legal and illicit substances can be associ-
ated with transient hallucinatory and delusional
experiences, community surveys have also linked sub-
stance use (SU; i.e. the use of a particular substance, but
not meeting diagnostic criteria for a disorder) and sub-
stance use disorders (SUDs) with an increased risk of psy-
chotic experiences (PEs), outside periods of acute
intoxication or withdrawal [1–6]. In particular, there is a
body of evidence linking cannabis use with an elevated
risk of PEs [1–5,7–9]. Recent studies have also linked com-
monly used substances such as tobacco and alcohol with
PEs [4,10–13]. For example, a 44-country study from
the World Health Survey found that current tobacco
smoking was associated with increased odds of life-time
PEs (OR = 1.35; 95% CI = 1.27–1.43) [10]. Illicit drugs
including cocaine, amphetamines and opioids have also
been linked with PEs [14–17].
Curiously, there is evidence that the relationship be-
tween PEs and SU/SUDs may be bidirectional. In our ear-
lier paper, we found that substance use disorders
(particularly alcohol abuse and dependence) were associ-
ated bidirectionally with PEs [18]. Several cohort studies
have found bidirectional association between PEs and can-
nabis use disorders [1,2,9,19,20]. These ﬁndings highlight
the importance of understanding the temporal sequence of
PEs and SU/SUDs. There is also strong evidence that famil-
ial factors may confound the apparent relationship be-
tween cannabis use and subsequent psychotic disorders
[21]. Based on these ﬁndings, there is a need for studies
that use temporally ordered variables to explore the bidi-
rectional associations between PEs and different types of
SUs (e.g. tobacco, cannabis, cocaine, alcohol, prescription
drugs, other illicit drugs). More complex models are also
required in order to determine how various types of
SU/SUDs inﬂuence the association between SU/SUDs and
PEs. For example, it is feasible that the presence of mental
disorders can inﬂuence the onset of PEs (e.g. a substance
use disorder may lead to a major depression, which leads
in turn to the onset of PEs). There is evidence that those
with SU/SUDs have an increased risk of mental disorders
[22,23], and there is a bidirectional relationship between
PEs and mental disorders [18]. Thus, it is reasonable to as-
sume that the association between PEs and SU/SUDs may
be explained at least in part by antecedent mental disor-
ders. Finally, there is a need to explore if there is a ‘dose–
response’ relationship between PEs (e.g. number of types
of PEs and frequency of PE episodes) and subsequent odds
of SU/SUDs.
The aims of the study were to extend previous ﬁndings
by examining: (1) the association between SUs or SUDs and
the subsequent onset of PEs; and conversely, (2) the associ-
ation between prior PEs and subsequent onset of SUs and
SUDs, (3) the inﬂuence of number or types of PEs and (4)
antecedent mental disorders together with comorbid
SU/SUDs on these associations.
METHODS
Samples
Data were drawn from 18 WMH surveys from the World
Health Organization (WHO) World Mental Health surveys
that included both the WHO Composite International
Diagnostic Interview (CIDI) psychosis module and items
related to substance use. Amulti-stage clustered area prob-
ability sampling strategy was used to select respondents
in majority of the surveys except for Belgium, Germany
and Italy. These three countries used municipal resident
registries to select respondents without listing households.
Details of each survey are presented in the Supporting
information, Table S1. The weighted average response rate
across all 18 surveys was 71.7%. Further information on
samples used for different substance use, details of proce-
dure and the assessment of mental disorders can be found
in the Supporting information, Table S2.
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Measures
Tobacco, alcohol and illicit drug use
All WMH surveys used the WHO CIDI (3.0), a fully struc-
tured diagnostic interview administered by trained lay in-
terviewers. Details of the assessments of tobacco, alcohol
and illicit drug use have been published elsewhere [24].
The tobacco and substance-use module of the CIDI in-
cludes an assessment of life-time occurrence and age at
ﬁrst initiation of alcohol, tobacco and each illicit drug
use. Respondents were asked if they had ever (i) used ciga-
rettes, cigars or pipe (tobacco use), (ii) smoked tobacco
daily for a period of at least 2 months (daily tobacco use),
(iii) drank alcohol (alcohol use), (iv) either marijuana or
hashish (cannabis use), (v) used cocaine in any form in-
cluding powder, crack, free base, coca leaves or paste (co-
caine use), (vi) used tranquillizers, stimulants, pain-killers
or other prescription drugs for non-medical reasons or
without the recommendation of a health professional
(henceforth extra-medical prescription drug use) or (vii)
used other drug such as heroin, opium, glue, lysergic acid
diethylamide (LSD), peyote or any other drug (other illicit
drug use).
Substance use disorders
The WHO CIDI version 3.0 was used to generate DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders,
4th edition) substance abuse or dependence disorders diag-
noses. The substance use disorders were nicotine depen-
dence, alcohol abuse, alcohol dependence, illicit drug
abuse and illicit drug dependence. The CIDI 3.0 does not al-
low for the diagnosis of cannabis use and/or dependence
disorder because there was no separate question for canna-
bis use or dependence. Some of the assessment details of
these disorders have been published elsewhere [25,26].
Standard hierarchy rules were applied, such that people
meeting criteria for DSM-IV dependence could not also
meet criteria for abuse for that substance.
A series of ﬁve questions was used to operationalize the
symptom criteria for alcohol abuse and a further 11 ques-
tions for alcohol dependence. These were asked of respon-
dents who (in the year they drank most) consumed
alcohol at or above a certain quantity/frequency threshold
of one or more drinks per week or, if drinking less often,
three or more drinks per day on the days they drank. For
extra-medical prescription drug use and illicit drug use dis-
orders, respondents were asked if they had ever used med-
icines for non-medical reasons or had ever used illicit
drugs, respectively. Those who reported life-time use were
then asked a series of questions: four questions for assessing
DSM-IV drug abuse and 11 questions to assess for drug
dependence (mapping to the seven DSM-IV criteria). Nico-
tine dependence was assessed using a similar method.
Respondents who reported smoking weekly were asked a
series of questions about the symptoms of nicotine depen-
dence (e.g. tolerance, withdrawal, smoking in larger
amounts or longer than intended, etc.). A number of initial
surveys in the WMH survey initiative (13 in this study)
only assessed symptoms of dependence among respondents
without a history of abuse. In order to improve the cross-
national comparability of estimates of SUDs, estimates for
alcohol and illicit drug dependence were used in these sur-
veys based on the method described in Lago et al. [27].
Psychotic experiences (PEs)
The CIDI Psychosis Module included questions about six PE
types—two related to hallucinatory experiences (visual
hallucinations, auditory hallucinations) and four related
to delusional experiences (thought insertion/withdrawal,
mind control/passivity, ideas of reference, plot to
harm/follow) (Supporting information, Table S2a, S2b).
The respondents were asked if they ever experienced each
PE (e.g. ‘Have you ever seen something that wasn’t there
that other people could not see?’; ‘Have you ever heard
any voices that other people said did not exist?’, etc.). Only
PEs occurring when the person was ‘not dreaming, not
half-asleep, or not under the inﬂuence of alcohol or drugs’
were included. With respect to the current research ques-
tions, it is important to note that hallucinations or delu-
sions that occurred ‘under the inﬂuence of alcohol or
drugs’ were excluded from all analyses. Age-at-onset of re-
spondents with PEs was also assessed. In this paper, we
present two key PE-related metrics: (a) number of PE types
(henceforth referred to as PE-type metric); and (b) fre-
quency of occurrence of PE episodes. We derived frequency
per year by dividing the number of PE episodes by the time
since onset of the PEs (age at interviewminus age of onset,
henceforth referred to as annualized frequency metric
[28].
Statistical analysis
In order to focus on the correlates of PEs in those
without psychotic disorders, we made the a priori
decision to exclude individuals who had PEs but who
also screened positive for possible schizophrenia/psychosis
or manic-depression/mania. In keeping with previous
publications [4,18,28–30] we excluded respondents who:
(a) reported (1) schizophrenia/ psychosis or (2) manic-
depression/mania in response to the question: ‘What did
the doctor say was causing (this/these) experiences?’; and
(b) those who ever took any antipsychotic medications for
these symptoms. This resulted in the exclusion of 139 re-
spondents (0.4% of all respondents), leaving 30902 re-
spondents for this study (Supporting information, Table S1).
The association between SU/SUDs and PEs was tested
using the Rao-Scott χ2. Discrete-time survival models
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operationalized as logistic regression with person-year as
the unit of analysis were used to investigate the bidirec-
tional relationship between PE and each of the SU or SUDs.
A person-year data set was constructed where each year
in the life of each respondent (up to and including the
age-at-onset of the outcome variables or age at interview,
whichever came ﬁrst) was treated as a separate observa-
tional record, with the year of outcome variable coded 1
and earlier years coded 0. When examining the predictive
relationship between prior SU/SUDs and the subsequent
onset of PEs, SU/SUDs that occurred in the same year as
PEs or following PEs were excluded. Those without PEs
were censored at their age at interview. For more details,
see Supporting information, Table S4. Similarly, when ex-
amining the relationship between prior PEs and subse-
quent onset of SU/SUDs, we excluded PEs that occurred
in the same year as SU/SUDs onset or following SU/SUDs.
A series of survival models was developed. The base model
(M1) was adjusted for age, sex, country and person-years.
We also examined a model that adjusted further for the
presence of other antecedent SU/SUDs (M2), and then ad-
ditionally for the presence of other antecedent mental dis-
orders (M3) (details can also be seen in Tables 2 and 3).
We also conducted two additional analyses: (1) to ex-
plore the impact of severity of PEs we repeated the survival
models (M3) for prior PEs to predict subsequent onset of
SU/SUDs using measures for both PE type metric (two or
more types versus one type) and PE annualized frequency
metric (dichotomized with a median split —more than
0.3 versus 0.3 or less episodes per year) in the models;
and (2) a post-hoc analysis examining the associations be-
tween PEs and subsequent onset of SUDs among those
with substance use only.
As theWMH data are both clustered and weighted, the
design-based Taylor series linearization implemented in
version 11 of SUDAAN software was used to estimate
standard errors and evaluate the statistical signiﬁcance of
coefﬁcients. All signiﬁcance tests were evaluated using
0.05-level two-sided tests.
RESULTS
The life-time prevalence of SU/SUDs for the total sample
and respondents with and without PEs are shown in
Table 1. Among the total sample 74.7% [standard error
(SE) = 0.4] of the respondents reported alcohol use while
only 7.7% (SE = 0.2) met criteria for alcohol use disorders.
Similarly, 51.0% (SE = 0.6) of the respondents reported to-
bacco use, whereas only 15.1% (SE = 0.4) had nicotine de-
pendence disorders. Overall, the prevalence of all measures
of SU/SUDs were higher among those with PEs compared
with those without PEs (χ21 ranges between 24.2 and
162.5, P < 0.001).
Table 2 Associations between temporally prior substance use (SU) and substance use disorders (SUDs) and subsequent onset of psychotic
experiences (PEs).
Multivariable (base) model (M1)a Multivariate model (M2)b Multivariate model (M3)c
OR (95% CI) OR (95% CI) OR (95% CI)
I. Odds of PE given prior onset of
Tobacco use 1.8* (1.4–2.3) 1.5* (1.1–2.0) 1.3* (1.0–1.8)
Daily tobacco use 1.6* (1.2–2.0) 1.3 (1.0–1.7) 1.1 (0.8–1.6)
Alcohol use 1.8* (1.5–2.1) 1.5* (1.2–1.8) 1.4* (1.1–1.7)
Cannabis use 1.6* (1.4–2.0) 1.2 (0.9–1.5) 1.0 (0.8–1.3)
Cocaine use 1.8* (1.3–2.4) 0.9 (0.7–1.3) 0.9 (0.7–1.3)
Extra-medical prescription drug use 2.1* (1.6–2.7) 1.7* (1.3–2.2) 1.5* (1.1–1.9)
Other illicit drug use 2.1* (1.6–2.7) 1.4* (1.0–1.8) 1.2 (0.9–1.6)
II. Odds of PE given prior onset of
Nicotine dependence 1.8* (1.4–2.3) 1.5* (1.1–2.0) 1.2 (0.9–1.6)
Alcohol use disorders 2.4* (1.9–3.0) 2.1* (1.6–2.7) 1.6* (1.2–2.0)
Alcohol abuse 2.1* (1.6–2.7) 2.0* (1.5–2.7) 1.6* (1.2–2.2)
Alcohol dependence 2.7* (2.1–3.6) 2.3* (1.7–3.2) 1.5* (1.1–2.1)
Illicit drug use disorders 2.3* (1.7–3.1) 1.3 (0.9–1.8) 1.0 (0.7–1.4)
Illicit drug abuse 1.7* (1.1–2.5) 1.0 (0.6–1.6) 0.9 (0.6–1.4)
Illicit drug dependence 3.2* (2.1–4.7) 1.6* (1.1–2.6) 1.0 (0.6–1.7)
*Signiﬁcant at the 0.05 level, two-sided test. aModel M1: each row represents a discrete-time survivalmodel of SU or SUDs as predictors of subsequent PE onset
adjusting for person-years, age cohorts, sex and country. bModel M2: (i) for life-time substance use, adjusted for other temporally prior substance use in ad-
dition to person-years, age cohorts, sex and country; (ii) for life-time substance use disorder, adjusted for other temporally prior substance use disorders in
addition to person-years, age-cohorts, sex and country. cModel M3: (i) for life-time substance use, adjusted for other temporally prior substance use and an-
tecedent mental disorders in addition to person-years, age cohorts, sex and country; (ii) for life-time substance use disorder, adjusted for other temporally prior
substance use disorders and antecedent mental disorders in addition to person-years, age-cohorts, sex,and country. OR = odds ratio; CI = conﬁdence interval.
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Associations between substance use, substance use
disorders and subsequent onset of psychotic experiences
First, we examined the associations between SUs and SUDs,
and the subsequent onset of PEs in the total sample
(Table 2). In the multivariable base model (M1) adjusting
for age-cohort, sex, person-years and country, all substance
use or SUDs were associated signiﬁcantly with increased
odds of subsequent onset of PEs. In the multivariate
model (M2), after adjusting for potential confounding
factors that included age-cohort, sex, person-years, coun-
try and temporally prior SU and SUDs, the odds ratios
(ORs) attenuated in all disorders while the associations
with daily tobacco use, cannabis use, cocaine use and illicit
drug abuse became non-signiﬁcant. After additional
adjustments with antecedent mental disorders (M3), those
with life-time tobacco use [OR = 1.3, 95% conﬁdence
interval (CI) = 1.0–1.8], alcohol use (OR =1.4, 95%
CI = 1.1–1.7) and extra-medical prescription drug use
(OR = 1.5, 95% CI = 1.1–1.9) each had increased odds
of subsequent onset of PEs. Unexpectedly, cannabis use
was not associated with subsequent onset of PEs in the
adjusted models. With respect to SUDs, alcohol use
disorders (both alcohol abuse and alcohol dependence
disorders) were associated with increased odds of subse-
quent PEs (alcohol abuse: OR =1.6, 95% CI = 1.2–2.2;
alcohol dependence: OR = 1.5, 95% CI = 1.1–2.1).
Associations between psychotic experiences and later
onset of SU/SUDs
In Table 3 we examined the associations between prior PEs
and subsequent onset of SU/SUDs. In the multivariable
base model (M1), temporally prior PEs were associated
with increased odds of subsequent onset of all types of
SU/SUDs. In the ﬁrst multivariate models (M2), after
adjusting for potential confounding factors (age-cohort,
sex, person-years, country and temporally ordered
SU/SUDs), the ORs for the associations attenuated, how-
ever, with additional adjustments with antecedent mental
disorders (M3), those with temporally prior PEs had in-
creased odds of subsequent tobacco use (OR = 1.5, 95%
CI = 1.2–1.9), alcohol use (OR =1.3, 95% CI = 1.1–1.6)
and cannabis use (OR =1.3, 95% CI = 1.0–1.5). Those
with PEs also had increased odds of subsequent onset of
nicotine dependence (OR=1.4, 95%CI = 1.1–2.0), alcohol
abuse (OR =1.5, 95% CI = 1.2–2.0) and alcohol
dependence (OR =1.4, 95% CI = 1.0–1.9) and illicit drug
dependence (OR =1.5, 95% CI = 1.0–2.3).
When we repeated the survival models (M3) exploring
the impact of severity of PEs on SU/SUDs that used PE
type and PE annualized frequency metrics, we found a
dose–response relationship between PEs and SU/SUDs
(Table 4). Those with two or more PE types (compared to
one type) had elevated ORs for alcohol use, cannabis use,
Table 3 Associations between temporally prior psychotic experiences (PEs) and subsequent onset of substance use (SU) and substance use
disorders (SUDs).
Multivariable (base) model (M1)a Multivariate model (M2)b Multivariate model (M3)c
OR (95% CI) OR (95% CI) OR (95% CI)
I. Prior onset of PE and odds of subsequent onset of
Tobacco use 1.8* (1.5–2.3) 1.7* (1.3–2.1) 1.5* (1.2–1.9)
Daily tobacco use 1.5* (1.2–1.8) 1.2 (1.0–1.5) 1.1 (0.9–1.4)
Alcohol use 1.4* (1.2–1.7) 1.4* (1.1–1.6) 1.3* (1.1–1.6)
Cannabis use 1.9* (1.6–2.3) 1.4* (1.1–1.7) 1.3* (1.0–1.5)
Cocaine use 1.8* (1.4–2.4) 1.1 (0.8–1.5) 1.1 (0.8–1.4)
Extra-medical prescription drug use 1.9* (1.5–2.3) 1.4* (1.1–1.7) 1.2 (0.9–1.5)
Other illicit drug use 2.1* (1.6–2.7) 1.2 (0.9–1.6) 1.1 (0.8–1.4)
II. Prior onset of PE and odds of subsequent onset of
Nicotine dependence 2.2* (1.7–2.8) 1.9* (1.4–2.4) 1.4* (1.1–2.0)
Alcohol use disorders 2.5* (2.0–3.0) 2.0* (1.6–2.6) 1.5* (1.2–2.0)
Alcohol abuse 2.1* (1.6–2.7) 1.9* (1.5–2.5) 1.5* (1.2–2.0)
Alcohol dependence 2.8* (2.1–3.6) 2.1* (1.5–2.9) 1.4* (1.0–1.9)
Illicit drug use disorders 2.8* (2.1–3.6) 1.8* (1.4–2.5) 1.5* (1.1–2.0)
Illicit drug abuse 2.2* (1.5–3.1) 1.6* (1.1–2.3) 1.4 (0.9–2.1)
Illicit drug dependence 3.4* (2.4–4.8) 2.3* (1.6–3.3) 1.5* (1.0–2.3)
*Signiﬁcant at the 0.05 level, two-sided test. aModel M1: each row represents a discrete-time survival model of PEs as predictors of subsequent SU or SUDs
onset adjusting for person-years, age cohorts, sex and country. bModel M2: (i) for life-time substance use, adjusted for other temporally prior substance use
in addition to person-years, age cohorts, sex and country; (ii) for life-time substance use disorder, adjusted for other temporally prior substance use disorders
in addition to person-years, age-cohorts, sex and country. cModel M3: (i) for life-time substance use, adjusted for other temporally prior substance use and
antecedent mental disorders in addition to person-years, age cohorts, sex and country; (ii) for life-time substance use disorder, adjusted for other temporally
prior substance use and antecedent mental disorders in addition to person-years, age-cohorts, sex and country. OR = odds ratio; CI = conﬁdence interval.
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cocaine use and alcohol or illicit drug use disorders.
The ORs ranged between 1.4 and 1.9 among those with
life-time SU, and between 1.5 and 1.9 among those with
SUDs. Similarly, those with more frequent PEs (compared
to those with less frequent PEs) had increased odds of to-
bacco use, alcohol use, nicotine dependence, alcohol use
disorders and illicit drug dependence, with similar gradi-
ents of risks as in PE types. When we repeated the survival
models (M3) by restricting our sample within substance
users only (as a post-hoc analysis), we found that PEs were
associated with an increased odds of transition to alcohol
abuse and alcohol use disorders (Supporting information,
Table S3).
DISCUSSION
Using temporally ordered analyses, we conﬁrm that the as-
sociations between SU/SUDs and PEs are bidirectional, and
that these associations mainly persisted after accounting
for other forms of prior SU/SUDs, demographic factors
and a wide range of antecedent mental disorders. Because
of the large sample size, we were also able to examine the
speciﬁc nature of these associations across different types
of both SUs and SUDs. In this way, we have extended our
own research that showed signiﬁcant bidirectional associa-
tions between PEs and certain types of SUDs (e.g. alcohol
use disorders) [18], and also previous research that focused
upon cannabis use disorders only [19].
Life-time tobacco use, extra-medical prescription drug
use and alcohol use and alcohol use disorders were all asso-
ciated with elevated odds of subsequent PEs after control-
ling for comorbid SU/SUDs and antecedent mental
disorders. Similarly, temporally prior PEs were associated
with subsequent onset of tobacco, alcohol and cannabis
use and all SUDs. In addition, we found a dose–response re-
lationship between PEs and subsequent onset of SU/SUDs
with more types or greater number of PEs were associated
with several SU/SUDs. The relationship persisted after con-
trolling for a range of potential confounding factors.
When we restricted the analysis of PEs to predict SUDs
among substance users, only the associations between PEs
and alcohol disorders remained signiﬁcant after adjusting
for antecedentmental disorders. Although PEswere associ-
ated with an overall risk in SUDs, among those with sub-
stance use they did not make an additional contribution
to the risk to other drug disorders or nicotine dependence,
suggesting that the presence of PEs did not alter the odds of
transitions from substance users to other drugs or nicotine
use disorders.
We also found that the associations between SU/SUDs
and PEs identiﬁed in multivariable models were attenuated
after adjustment with 21 antecedent mental disorders.
Table 4 Associations between psychotic experiences (PEs) (two or more versus one PE type, more than 0.3 annualized episodes versus 0.3
or less) and subsequent onset of substance use (SU) and substance use disorders (SUDs).
2 or more PE typesa > 0.3 episodes per yearb
OR (95% CI) OR (95% CI)
I. Life-time substance use
Tobacco use 1.5 (0.9–2.3) 1.5* (1.0–2.1)
Daily tobacco use 0.9 (0.6–1.2) 1.2 (0.9–1.8)
Alcohol use 1.5* (1.1–1.9) 1.4* (1.1–1.8)
Cannabis use 1.4* (1.1–1.9) 1.2 (0.9–1.5)
Cocaine use 1.9* (1.3–2.8) 1.2 (0.9–1.8)
Extra-medical prescription drug use 1.2 (0.8–1.9) 1.0 (0.7–1.4)
Other illicit drug use 0.9 (0.6–1.4) 1.0 (0.7–1.5)
II. Life-time substance use disorder
Nicotine dependence 1.5 (0.9–2.3) 1.6* (1.1–2.3)
Alcohol use disorders 1.5* (1.0–2.1) 1.6* (1.3–2.1)
Alcohol abuse 1.3 (0.8–2.1) 1.2 (0.8–1.8)
Alcohol dependence 1.9* (1.3–2.9) 2.0* (1.4–2.9)
Illicit drug use disorders 1.6* (1.1–2.3) 1.4 (1.0–2.0)
Illicit drug abuse 1.7* (1.0–2.9) 1.2 (0.7–2.2)
Illicit drug dependence 1.6 (1.0–2.7) 1.7* (1.1–2.6)
*Signiﬁcant at the 0.05 level, two-sided test. aEach row represents a discrete-time survival model of two or more PE types (ref: one PE type) as predictors of
subsequent SU or SUDs. (i) For life-time substance use, adjusted for other temporally prior substance use and antecedent mental disorders in addition to per-
son-years, age cohorts, sex and country; (ii) for life-time substance use disorder, adjusted for other temporally prior substance use and antecedent mental dis-
orders in addition to person-years, age-cohorts, sex and country. bEach row represents a discrete-time survival model of more than 0.3 annualized episodes
(ref: ≤ 0.3 episodes) as predictors of subsequent SU or SUDs. (i) For life-time substance use, adjusted for other temporally prior substance use and antecedent
mental disorders in addition to person-years, age cohorts, sex and country; (ii) for life-time substance use disorder, adjusted for other temporally prior sub-
stance use, and antecedent mental disorders in addition to person-years, age-cohorts, sex and country. OR = odds ratio; CI = conﬁdence interval.
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This was not surprising, given that previous research sug-
gested that prior PEs increased the risk of mental disorders
later in life [20], and given the extensive comorbidity be-
tween different types of substance use andmental disorders
[31]. However, even after these adjustments, we identiﬁed
appreciable ORs between several patterns of SU/SUDs and
subsequent PEs and vice versa. These ﬁndings lend weight
to the hypothesis that the presence of antecedent mental
disorders does not account entirely for the relationship be-
tween SU/SUDs and PEs in either direction.
Although we found signiﬁcant associations between
cannabis use and subsequent onset of PEs in the bivariate
model, this association did not persist after adjustment for
the range of covariates we considered here, which included
demographics, other temporally prior substance use and
antecedent mental disorders. This is in contrast to cohort
studies that included similar covariates [32]. This discrep-
ancy may be due partly to methodological differences, as
our analysis controlled for a much wider range of anteced-
ent mental disorders than previous analyses, and excluded
samples those with onset of PEs and SU/SUDs in the same
year. Additionally, the mechanism of effect may be that
cannabis induces PEs in those already vulnerable to
developing such symptoms. We did not examine the age-
at-onset of PEs among those who used (or did not use) sub-
stances, but previous research has suggested that cannabis
may serve largely to decrease the age-at-onset of psychosis
(rather than increasing incidence) [33]. PEs and substance
use disordermay share common risk factors (e.g. traumatic
life events, family history). Previous research found that
the association between PEs and SUDs persisted after
adjusting for trauma and victimization [4].
Although a signiﬁcant body of evidence has linked
SU/SUDs with subsequent PEs, the biological mechanisms
underpinning the association are yet to be established.
Some commentators have suggested that substance use
may contribute to dysregulation of dopamine neurotrans-
mission which, in turn, may contribute to vulnerability to
psychosis [34]. However, a recent meta-analysis with 24
studies found little evidence to suggest that cannabis use
affects dopamine release in striatal and pre-frontal areas
among healthy subjects [35].
Several of the ﬁndings from this study warrant addi-
tional research, given their potential clinical and public
health signiﬁcance. First, the prevalence of SU/SUDs was
higher among people who had experienced PEs, and fur-
ther, that people who had experienced PEs also had greater
odds of a range of different types of SUDs if they had en-
gaged in use of any of the substances we examined here.
The health risks of heavy tobacco use in particular are a
concern, especially among more vulnerable and marginal-
ized populations, which includes people with mental
health problems, for whom it may also be more difﬁcult
to cease use. Secondly, once PEs have developed in an
individual, the continued use of substances with psychoac-
tive effects is of clinical concern, particularly in the case of
alcohol and cannabis, which are the most commonly used
substances. There is consistent evidence that continued
substance use among people who have developed mental
health problems increases risks for poorer mental health
outcomes [36]. Our ﬁndings also provide a heuristic frame-
work for the generation of new hypothesis related to PEs in
future studies. For example, in light of the dose–response
relationship between PEs and subsequent SU/SUDs, it will
be of interest to see what proportion of early- versus late-
onset PEs are linked to SU/SUDs and multiple use of sub-
stance use, as well as to explore if particular types of PEs
(e.g. hallucinations, delusions) are associated differentially
with particular types of SU/SUDs as a complex function
of age at onset, time since onset and existence of complex
comorbidities. As noted earlier, familial factors (e.g. genetic,
shared environment) could confound the apparent rela-
tionships between the variables of interest [21], in which
case public health interventions designed to reduce the
prevalence of exposure to SU/SUDsmay not translate to re-
ductions in the onset of subsequent PEs.
While the current study has several strengths (large
sample size from many countries, consistent methods and
standardized measures of data collection and temporally
sequence the variables of interest), the study has several
limitations. First, although we excluded people who were
screen-positive for possible psychotic disorders, the WMH
surveys were administered by lay interviewers, and clinical
validation of CIDI diagnoses was not available. Respon-
dents may underestimate their use of substances—this
type of bias would reduce our ability to detect a true asso-
ciation between the variables of interest. Secondly, our
studieswere based on cross-sectional studies and retrospec-
tive reports about age-at-onset of PEs, SUDs and mental
disorders which, although obtained rigorously [37], would
be subject to some level of recall bias. While we note that
several prospective studies have conﬁrmed the association
between SUDs and PEs [1,5,19], observational studies can-
not determine causal pathways. Thirdly, our measure of
cannabis use was onset of ﬁrst-time use (not more frequent
use), which may have contributed to our lack of signiﬁcant
ﬁndings between cannabis use and subsequent PEs. More-
over, the data did not allow us tomeasure cannabis use dis-
orders in this study. Finally, it was also not possible to
analyse those who had limited alcohol use versus heavy
users because there were no separate questions for this in
the WMH CIDI.
In summary, this study sheds new light upon the rela-
tionship between PEs and SU/SUDs. Although arguments
continue whether SU/SUDs are associated causally with
PEs [38], our temporally ordered analysis conﬁrms that
the relationship between various SU/SUDs and PEs is bidi-
rectional, and independent of antecedent mental disorders.
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These ﬁndings have both clinical and public health signiﬁ-
cance, given that SU/SUDs and psychosis are important
predictors of adverse health outcomes [39].
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